Clincosm LogoSign in Get a demo

PC: Periosteal Chondrosarcoma: a Single Institution Experience

Sponsor
Istituto Ortopedico Rizzoli (Other)
Overall Status
Completed
CT.gov ID
NCT05511883
Collaborator
(none)
55
Enrollment
1
Location
18
Actual Duration (Months)
3.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Periosteal chondrosarcoma is a low-grade, malignant cartilaginous bone neoplasm that arises on the surface of bone, predominantly in the metaphysis of long bones.

Periosteal chondrosarcoma is an infrequent chondrosarcoma subtype which accounts for less than 1% of all chondrosarcomas (1) and has a peak incidence in the fourth decade (2).

It has a reported incidence of local recurrences of 13-28% and a low metastatic potential, with distant recurrences occurring mostly in lungs (3).

Contrary to conventional chondrosarcomas, grading of periosteal chondrosarcomas seems not to predict prognosis. IDH1 and IDH2 mutations, characteristics of central chondromas/chondrosarcomas, have been also found in a subset of periosteal chondrosarcomas (1, 4).

These observations are based on the results from smaller series of cases (1, 5, 6), although the impact of histopathological characteristics on survival, local recurrence and metastases should be assessed in larger series of cases.

The aim of the present study is to review all the cases with a diagnosis of primary periosteal chondrosarcoma treated at the Rizzoli Institute from 1900 up to 31 December 2019, retrospectively.

The study will exam all the clinical, radiological, and histological features of this tumor with regard importance of medullary involvement, the IDH1/2 gene status, the types of treatment, the status of surgical margins, the presence of progression (dedifferentiation) areas and the relationship of these factors to individual outcome.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    55 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Retrospective
    Official Title:
    Periosteal Chondrosarcoma: a Single Institution Experience
    Actual Study Start Date :
    Apr 1, 2020
    Actual Primary Completion Date :
    Dec 15, 2020
    Actual Study Completion Date :
    Sep 30, 2021

    Outcome Measures

    Primary Outcome Measures

    1. Periosteal Chondrosarcoma: a single institution experience [act baseline]

      the IDH1/2 gene status.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Male and female patients treated at Rizzoli Institute from 01 Jan 1900 to 31 Dec 2019

    • Diagnosis of peristeal chondrosarcoma

    • Written informed consent prior to any study-specific analysis and/or data collection

    Exclusion Criteria:
    • Patients with histological diagnosis different from periosteal chondrosarcoma.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 IRCCS- Istituto Ortopedico Rizzoli Bologna Italy 40136

    Sponsors and Collaborators

    • Istituto Ortopedico Rizzoli

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Alberto Righi, MD, PhD, Istituto Ortopedico Rizzoli
    ClinicalTrials.gov Identifier:
    NCT05511883
    Other Study ID Numbers:
    • 136/2020
    First Posted:
    Aug 23, 2022
    Last Update Posted:
    Aug 23, 2022
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Chondrosarcoma

    Study Results

    No Results Posted as of Aug 23, 2022